论文部分内容阅读
目的:观察应用降纤酶治疗急性缺血性脑血管病的临床疗效。方法:将急性缺血性脑血管病患者100例随机分为治疗组和对照组,各组50例,在给予综合性基础治疗的基础上治疗组给予降纤酶治疗,对照组给予血塞通治疗,观察两组神经功能缺损评分、临床疗效和血浆纤维蛋白原含量变化。结果:经治疗后治疗组有效(基本痊愈+显著进步)率为74.0%;对照组有效(基本痊愈+显著进步)率为34.0%。治疗组总有效率明显高于对照组,差异有统计学意义(P<0.05),治疗组神经功能缺损评分明显低于对照组(P<0.05),同时治疗组降低血浆纤维蛋白原疗效明显优于对照组(P<0.05)。结论:应用降纤酶治疗急性缺血性脑血管病是一种有效的方法。
Objective: To observe the clinical efficacy of defibrase in the treatment of acute ischemic cerebrovascular disease. Methods: 100 patients with acute ischemic cerebrovascular disease were randomly divided into treatment group and control group, 50 cases in each group, on the basis of comprehensive basic treatment, the treatment group was treated with defibrase, while the control group was given Xuesaitong The changes of neurological deficit score, clinical curative effect and plasma fibrinogen content were observed. Results: After treatment, the effective rate (basic recovery + significant improvement) in the treatment group was 74.0%. The effective rate (basic recovery + significant improvement) in the control group was 34.0%. The total effective rate of the treatment group was significantly higher than that of the control group, the difference was statistically significant (P <0.05), the score of neurological deficit in the treatment group was significantly lower than that of the control group (P <0.05), while the therapeutic effect of reducing fibrinogen in the treatment group was obvious In the control group (P <0.05). Conclusion: The application of defibrase in the treatment of acute ischemic cerebrovascular disease is an effective method.